Clinical trial
Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab with Metformin As Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer
NCT02488564 is registered in ClinicalTrials.gov with Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab with Metformin As Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 17, 2014
- Completion date
- March 17, 2020
- Enrollment
- 49 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
her-2 positive breast cancer